(Q34928181)

5 August 2017

1 reference

title

Neurotoxic effects of GABA-transaminase inhibitors in the treatment of epilepsy: ocular perfusion and visual performance (English)

1 reference

5 August 2017

1 reference

Sarah L Hosking

1

1 reference

5 August 2017

Emma J Roff Hilton

series ordinal

2

1 reference

5 August 2017

publication date

1 September 2002

1 reference

Ophthalmic and Physiological Optics

5 August 2017

published in

1 reference

5 August 2017

volume

22

1 reference

5 August 2017

issue

5

1 reference

5 August 2017

page(s)

440-447

1 reference

Hypercapnia-induced cerebral and ocular vasodilation is not altered by glibenclamide in humans

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1475-1313.2002.00063.X

Effect of dexamethasone therapy on cerebral and ocular blood flow velocity in premature infants studied by colour Doppler flow imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1475-1313.2002.00063.X

The effects of vigabatrin on electrophysiology and visual fields in epileptics: a controlled study with a discussion of possible mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1475-1313.2002.00063.X

Vigabatrin effect on inner retinal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1475-1313.2002.00063.X

Localization of GABA, glycine, glutamate and tyrosine hydroxylase in the human retina

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1475-1313.2002.00063.X

Symptomatic and asymptomatic visual loss in patients taking vigabatrin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1475-1313.2002.00063.X

Diversity of GABA receptors in the vertebrate outer retina

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1475-1313.2002.00063.X

Pharmacological characterization of GABA receptors mediating vasodilation of cerebral arteries in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1475-1313.2002.00063.X

Severe persistent visual field constriction associated with vigabatrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1475-1313.2002.00063.X

GABA-gated Cl- channels in the rat retina

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1475-1313.2002.00063.X

Gamma-aminobutyric acid receptor on vascular smooth muscle of dog cerebral arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1475-1313.2002.00063.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1475-1313.2002.00063.X

Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1475-1313.2002.00063.X

Long term changes in the visual fields of patients with temporal lobe epilepsy using vigabatrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1475-1313.2002.00063.X

Physiological perturbation of ocular and cerebral blood flow as measured by scanning laser ophthalmoscopy and color Doppler imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1475-1313.2002.00063.X

Visual function loss from vigabatrin: effect of stopping the drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1475-1313.2002.00063.X

Visual field defects with vigabatrin: epidemiology and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1475-1313.2002.00063.X

Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1475-1313.2002.00063.X

Visual field defects associated with vigabatrin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1475-1313.2002.00063.X

Clinical ictal patterns in epileptic patients with occipital electroencephalographic foci.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1475-1313.2002.00063.X

A controlled study of vigabatrin and visual abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1475-1313.2002.00063.X

Interictal cerebral and cerebellar blood flow in temporal lobe epilepsy as measured by a noninvasive technique using Tc-99m HMPAO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1475-1313.2002.00063.X

Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1475-1313.2002.00063.X

Brain glutathione levels in patients with epilepsy measured by in vivo (1)H-MRS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1475-1313.2002.00063.X

Development of tolerance to the effects of vigabatrin (gamma-vinyl-GABA) on GABA release from rat cerebral cortex, spinal cord and retina

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1475-1313.2002.00063.X

Color vision in epilepsy patients treated with vigabatrin or carbamazepine monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1475-1313.2002.00063.X

Contrast and glare sensitivity in epilepsy patients treated with vigabatrin or carbamazepine monotherapy compared with healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1475-1313.2002.00063.X

Neuroprotection in relation to retinal ischemia and relevance to glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1475-1313.2002.00063.X

Activity-dependent transport of GABA analogues into specific cell types demonstrated at high resolution using a novel immunocytochemical strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1475-1313.2002.00063.X

Patients treated with vigabatrin exhibit central visual function loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1475-1313.2002.00063.X

Visual field constriction: accumulation of vigabatrin but not tiagabine in the retina.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1475-1313.2002.00063.X

The effect of vigabatrin (gamma-vinyl GABA) on cerebral blood flow and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1475-1313.2002.00063.X

The influence of established and new antiepileptic drugs on visual perception. II. A controlled study in patients with epilepsy under long-term antiepileptic medication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1475-1313.2002.00063.X

Molecular basis of glutamate toxicity in retinal ganglion cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1475-1313.2002.00063.X

Oxidative stress and antioxidants in epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1475-1313.2002.00063.X

Antiepileptic drugs and cerebral glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1475-1313.2002.00063.X

Concentric visual field restriction under vigabatrin therapy: extent depends on the duration of drug intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1475-1313.2002.00063.X

The Hospital for Sick Children, Toronto, Longitudinal ERG study of children on vigabatrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1475-1313.2002.00063.X

Characteristics of a unique visual field defect attributed to vigabatrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1475-1313.2002.00063.X

10.1046/J.1475-1313.2002.00063.X

21 January 2018

Identifiers

DOI

1 reference

5 August 2017

1 reference